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Financial modeling is the process of building models of a real-world financial situation.  This 
process is a mathematical model designed to represent the performance of a financial asset 
or portfolio of a business, project, or any other investment. 
 
The financial modeling is an exercise in either asset pricing or corporate finance, of a 
quantitative nature. Its principal objective is translating a set of hypotheses about the behavior 
of markets or agents into numerical predictions. This term is also known as a general term 
that means different things to different users; this term can be related either to corporate 
finance applications or to quantitative finance applications.  In this modeling we are going 
to analyze a company called Medtronic. This is a company with a strong competitive position 
and the exercise is about a Hold recommendation for Medtronic. 
 
This report was originally made as the final project for FIN 217F - Corporate Financial 
Modeling course enrolled during fall 2018 in Brandeis University, it was homologated as 
part of the double degree process as the dissertation of the Master in Financial Management 








The importance of financial modeling relies on its capability to get better financial decisions 
within a firm. It is used for the purpose of future planning. This method is accomplished by 
simulating the impact of important variables where financial modeling allows for scenario 
preparation so that organization knows its course of action in various situations that may 
arise. 
 
Financial modeling also plays an important role in capital budgeting. It also helps in 
determining the cost of capital. It provides a thorough analysis of debt/equity structure for 







Issue a hold recommendation for the study project. 
 
Specific 
• To issue a company overview and the company key success drivers 
• To issue the company risk factors 







Medtronic PLC (Medtronic) develops and manufactures therapeutic medical devices for 
chronic diseases and specialized surgical interventions. The company sells its products to 
healthcare institutions and physicians in more than 140 countries around the world. Sales in 
2018 were US$29.9 billion and the company assets worth US$94.5 billion. Revenues in the 
U.S accounted for 53%, while 47% came from emerging markets and other developed 
countries.  
 
The company has a diversified portfolio of products divided in four big segments: Cardiac 
and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes. Medtronic 
is the biggest player in the U.S. Medical Device Manufacturing industry, accounting for 40% 
of the market share. Its success has been based on high investment in R&D, which allows 
them to be in the technological frontier of biomedical developments, and strategic business 
management. While an increasingly growing market, the international expansion and 
technological competitive advantages are considered to be the company’s main drivers, the 
political uncertainty that surrounds government initiatives like Medicare, tougher FDA 
regulations and potential product recalls are viewed as the key business risks.  
 
Worldwide aging population is rising- with forecasts suggesting that by 2050 there will be 
more people aged +60 than people aged 10 to 24- and that is one of the main drivers of the 
industry, which is characterized by high concentration and high government regulations. 
Competition within the industry is intense and many merges and acquisitions have occurred 
in the last decades. When analyzing industry forces, the threat of new entrants is moderate to 
low; threat of substitutes is moderate, bargaining power of supplier is low, bargaining power 
of customers is moderate to high and rivalry is high.  
 
A valuation based on the Discounted Free Cash Flow was conducted and the base-case 
scenario yield a stock price of $93.04, which is very close to the closing price of US$94.02 
on Dec 1st, 2018. Best and Worst scenarios showed prices of US$163.49 and US$58.37. A 




Equity yield 8.38% and the After-Tax WACC yield 7.5%; while the long-term growth was 
assumed at 3%, according to industry forecasts.  A Multiple Valuation was also done, with 
prices ranging from US$84.72 to $152.68.  
 
Based on the company strong competitive position, the risk factors and the results from the 
valuation model, we issue a Hold recommendation for Medtronic. The company is stable, 
has proven to have successful business strategies and its main end-users (population aged 60 
or more) are forecasted to keep growing.  We believe it will have stable free cash flows in 
the future, nonetheless, there are many regulations and uncertain political factors that may 
affect the company growth, which is already in a mature life-cycle with moderate growth 
perspective. 
 
1. Company Overview 
 
Medtronic (MTD) is one of the largest medical device company in the world. Founded in 
1949 as a medical equipment repair shop, it is currently a $94.5 billion biomedical 
engineering company and has operations in 370 locations and 160 countries. In January 2015, 
the Company acquired the rival brand Covidien, resulting in an increase of their market, 
which is now 40% in the U.S. market.  
   
MDT develops and manufactures therapeutic medical devices for the treatment of chronic 
diseases, high risk surgical interventions and pain relief. At the end of fiscal year 2018, it 
recorded revenues of US$30 Billion derived from four segments: Cardiac and Vascular group 
(11.4B), Minimally Invasive Therapies group (8.7B), Restorative Therapies group (7.7B) and 
Diabetes group (2.1B).   
 
2. Company’s Key Success Drivers 
 
Serving an increasingly growing market 
According to the United Nations, “population ageing is becoming one of the most significant 




people aged +60 years than people aged 10-24 years. Due to this phenomenon, the statistic 
related with the prevalent diseases- 53% related with obesity, cardiac and diabetes- and 
chronic diseases have an upward trend (Evaluate MedTech, 2018). This translates into more 
visit to healthcare institutions, increasing the number of medical procedures and domestic 
care, in which Medtronic has a predominant role. Medtronic has high recognition, a wide 
portfolio of products with more than 46,000 registered patents and constant innovations to 
attend the future demand of the market. 
 
Big Data competitive advantage 
Monitoring diseases and forecasting health events to be able to link patients’ medical devices 
with measurable outputs is a top priority for Medtronic in order to improve their technologies 
and feed their databases for research purposes. The success of this strategy relies in the 
demand of a new generation of patients that want to be empowered of their own health and 
value more than ever before the availability of real-life data. 
 
International expansion 
Cardiac and Vascular and Minimal Invasive Therapies segments combined account for a 67% 
of the Company’s revenue and its growth is mostly driven by emerging economies, due to 
the increasing population and economic growth in those markets, which rises the willingness 
of governments and citizens to spend in healthcare. Those factors were recognized by MDT 
and become part of their strategy more than a decade years ago and nowadays foreign sales 
account for more than 40.0% of the company’s total revenue (Curran, 2018). 
 
Minimal invasive robots booming 
Minimally invasive procedures have become the gold standard for an increasingly number 
of surgical procedures and more consumers are now demanding this kind of surgeries over 
the traditional ones. This market is expected to grow, globally, at an average of 8% annually 
from 2018 to 2025 (BIS Research, 2018). Medtronic fully entered the market of Minimal 
Invasive devices in late 2014 and by 2018 they already had 27.6% of the global market share, 
mainly due to its heavy investment in R&D, which allows them to outpace their competitors 





3. Company’s Risk Factors 
 
FDA requirements 
It takes several months to obtain FDA approval to launch a new device. U.S. regulations are 
getting tougher and approval time can now be longer and more costly for some devices that 
are in the technology frontier. This can represent a thread not only because investment in 
R&D might take longer to start generating revenues, but also because it opens a window for 
competitors to get deeper knowledge of Medtronic’s new developments before they get to 
the market, which gives them more time to set a strategy and even start developing similar 
products to compete with.     
 
Product recall 
During the past year Medtronic had more than 5 product recalls, which negatively impacted 
their sales in fiscal year ended in 2018.  It is unlikely that Medtronic can always be in total 
compliance with FDA, especially because many of their products’ features will be known 
after field trials and consumer experiences and feedback. Any future recall might hurt the 
Company’s reputation and revenues and will also imply extra expenditure in R&D.  
 
Government regulation and political uncertainty  
The uncertainty that surrounds the U.S. Healthcare reform is probably the number one 
concern for Medtronic at the moment. As of today, population’s access to medical assistance 
in the U.S. depends highly on government-funded initiatives such as Medicare and Medicaid. 
A decrease in healthcare public expenditure will directly affect the number of devices sold 
to hospital and individuals, which are Medtronic main customers in the local market. 
Similarly, trade reforms and foreign government regulations are also a concern because they 
can set entry barriers to new interesting markets, thus disturbing Medtronic’s expansion 





4. Industry Dynamics 
The overall industry is in a moderate growing stage due to the aging baby boomer’s 
population and the progressive need of replacing technologies in health care system services. 
The forecasted annualized long-term growth rate of the industry is 3% (Curran, 2018). 
Competition within the industry is intense and small companies can have a hard time to 
survive, which has led to many merges and acquisitions in the last decade. It is expected that 
this trend will continue, as big players gain more capacity to absorb smaller ones.  
 
The increased demand of biomedical developments, the use of Artificial Intelligence and fast 
manufacture technology will allow to modify cost structures across the industry and expand 
the size of the at-home healthcare market. Equipment for cardiovascular, neurological and 
obesity related diseases are expected to lead the growth of the industry since these are the 
chronic  diseases that are more rapidly rising not only in the U.S., but in the world (World 
Helath Organization, 2018).  
   
Porter’s Five Forces Analysis 
According to the medical device industry characteristics, Porter´s five forces categorization 
is as follow:  
 
Threat of new entrants: Moderate to low 
This industry has high profits margins and this increase its attractiveness. Nevertheless, due 
to high competition, high concentration, heavy regulation and high expenditures (12% of 
revenue in R&D), competitors interested in entering this market will find a challenging 
environment with a fast rate of technological change, high cost of development and really 
expensive unexpected claims. 
 
Threat of substitutes: Moderate 
As technology rapidly evolves, there are now more medical developments, especially 
surgical procedures, which eliminates the need to permanently use other types of devices. 
Similarly, pharmaceutical medicine is constantly evolving, generating drugs that can prevent 




substitutes over time, this is why the substitutes producers are not limited to the ones that 
coexist in the health care manufacturers companies, hospitals and medical research are also 
an important part of substitute’s designers. 
 
Bargaining Power of Supplier: Low 
Due to the use of generic parts and self-development materials, the supplier’s power is low. 
Companies do not rely just in one producer because there are several companies with similar 
raw material. At the same time, globalization has led to a low-cost policy in raw material 
suppliers. 
 
Bargaining Power of Customers: Moderate to High 
Few decades ago, customers did not have a big power in this industry supply chain. However, 
there are now more alternatives and more brands to choose from and generic products became 
available for some devices, factors that have given customers a higher bargaining power.  
 
Competitive Rivalry: High 
Competition in this industry is extremely high since a product needs to comply with many 
factors to be successful: reliability, clinical outcomes, doctors’ perceptions, patients’ 
experiences and affordability. As government and healthcare providers push for price 
concessions, price has become more important and the competition is now tougher. 
 
5. Company Financial Performance 
 
In mid-2017 the Company divested three of its units: Patient Care, Deep Vein Thrombosis, 
and Nutritional Insufficiency.  This led to a decrease in reported sales of the Minimally 
Invasive Therapies segment of 12%, as sales from the divested units used to be recorded 
under this segment. Even though this hurt its financial performance for the last fiscal year, 
the Company believes that new acquisitions will more than offset this downturn in the long-
run. On the other hand, in 2018 Medtronic acquired three smaller companies: Nutrino, Mazor 
Robotics and Vision Sense, these acquisition will not prove its worth until be completely 





For fiscal year 2018, net sales in the U.S. were down by 5%, which was partially offset by 
an increase of 6% in developed markets outside the U.S. and 12% in emerging markets, 
generating a total net sales growth of 0.8%.  From 2015 to 2016, revenues increased by 19%, 
42% and 4%, respectively. Sales in 2015 were particularly high due to the acquisition of 
Covidien.  
 
The current EBIT ratio is 22.2%, more than double of the industry average (9.72%). 
Similarly, the Net Profit margin in 2018 was 12.3%, almost three times higher than its peer’s 
average of 5.71% (Mercer Capital, 2017).  
 
From 2015 to 2018, Return on Assets and Return on Equity have gone from 2.3% to 3.9% 
and 5.0% to 6.8%, respectively, which indicates an increase in capital utilization.  
 
The company has had an almost constant capital structure of 50% debt in the last five years, 
with an investment grade. Standards & Poor’s rated the Medtronic’s long-term debt as A 
(stable) and Moody's as A3; these rating has maintained average interest rates on long-term 
debt at around 4%. It is also important to mention that the Company’s Interest Coverage ratio 




6. Valuation Model 
 
We decided to use a top-bottom methodology, using industry research information for 
approximation and benchmark for assumptions of segments growth, litigation process 
provisions, research and developments and capital expenditures. Historical data was also 
useful to understand the non-core business expenses and other investments behaviors. 
Company information (10-K) and fiscal year 2019 guidance were used in order to build 





The Beta of the Company was calculating using monthly returns from 2008-2018, the market 
risk premium was assumed to be 5.68% (Damodaran, 2018) and the 10-year U.S. Treasury 
Bond yield of 2.89% was used as the risk free rate. Using the CAPM, Cost of Equity yield 
8.38% and for the Cost of Debt it was used the weighted average effective rate on outstanding 
bonds (4.02%). With a corporate tax of 21%, the Weighted Average Cost of Capital yield 
7.5%. Long-term growth rate for the base line scenario was assumed to be 3%, in accordance 
with industry performance and industry expected future growth rates (Curran, 2018).  
      
7. Results 
 
The valuation base in DCF model gave a share price of US$93.04 in the base-case scenario, 
US$163.49 in the best-case scenario and US$58.37 under the worst-case.  Additionally, the 
valuation by comparable yield US$82.0 (price-to earnings), US$94.30 (price-to-sales), 
US$125.75 (EV/EBITDA) and US$148.51 (EBIT/EBITDA). It is noticed that the DCF base-
line price was very close to the price-to-sales result. As of Dec 1st, 2018, Medtronic’s stock 
price closed at $94.2.  
 
A sensitivity analysis was also conducting, with different combinations of WACC and long-
term growth rates, yielding prices from US$47.4 to US$185.5. The key factors used in the 
scenario valuation were: a) growth rate for each segment, b) cost of capital and c) terminal 









Based on the company strong competitive position within the local and global market, the 
risk factors analyzed in previous sections and the results from the valuation model, we issue 
a Hold recommendation for Medtronic PLC. The company is strong, have proven to have 
successful business strategies and its main end-users (population aged 60 or more) are 
forecasted to keep growing up to a point that they will double young and adolescents by 2050.    
 
We believe Medtronic will have stable free cash flows in the future, nonetheless, there are 
many regulations and uncertain political factors that may affect the company growth. 
Additionally, Medtronic is already in a mature life-cycle and the industry is expected to grow 
at a moderate 3% in the long run. These are the main reasons we are not giving a solid Buy 







• One of the applications of financial modeling may be business valuation that is 
deciding the fair value for a business.  
• Other applications of financial modeling is organization’s decision making and 
scenario preparation.  
• Financial modeling is used by organizations for future planning their long term goals 
according to different situations that may arise. 
• Capital budgeting -financial modeling helps companies determine allotting resources 
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